Edition:
India

Progenics Pharmaceuticals Inc (PGNX.OQ)

PGNX.OQ on NASDAQ Stock Exchange Global Select Market

7.00USD
1:30am IST
Change (% chg)

$-0.02 (-0.28%)
Prev Close
$7.02
Open
$7.00
Day's High
$7.06
Day's Low
$6.95
Volume
168,194
Avg. Vol
343,299
52-wk High
$8.63
52-wk Low
$4.61

Latest Key Developments (Source: Significant Developments)

Progenics Pharmaceuticals Announces FDA Acceptance Of Marketing Application For Azedra In Pheochromocytoma And Paraganglioma
Friday, 29 Dec 2017 

Dec 29 (Reuters) - Progenics Pharmaceuticals Inc ::PROGENICS PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR AZEDRA® (IOBENGUANE I 131) IN PHEOCHROMOCYTOMA AND PARAGANGLIOMA.PROGENICS PHARMACEUTICALS - ‍FDA GRANTED CO REQUEST FOR PRIORITY REVIEW; HAS SET ACTION DATE OF APRIL 30, 2018 UNDER PDUFA​.  Full Article

Progenics Pharmaceuticals Q3 loss per share $0.22
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Progenics Pharmaceuticals Inc :Progenics Pharmaceuticals announces third quarter 2017 financial results and business update.Q3 loss per share $0.22.Q3 earnings per share view $-0.23 -- Thomson Reuters I/B/E/S.Progenics Pharmaceuticals Inc - ‍Q3 revenue totaled $2.7 million, down from $53.9 million in Q3 of 2016​.Progenics - ‍ended Q3 with cash and cash equivalents of $98.3 million, decrease of $40.6 million versus cash and cash equivalents as of December 31, 2016​.  Full Article

Progenics Pharmaceuticals announces positive topline results from registrational Phase 2B trial of Azedra®
Thursday, 30 Mar 2017 

Progenics Pharmaceuticals Inc : Progenics Pharmaceuticals announces positive topline results from registrational phase 2b trial of azedra® . Progenics Pharmaceuticals Inc - study achieves primary endpoint . Progenics Pharmaceuticals Inc - secondary endpoint shows favorable tumor response to therapy .Progenics Pharmaceuticals Inc - company to submit nda in mid-2017.  Full Article

Progenics Pharmaceuticals Q2 loss per share $0.08
Thursday, 4 Aug 2016 

Progenics Pharmaceuticals Inc : Q2 loss per share $0.08 . Progenics Pharmaceuticals announces second quarter 2016 financial and business results . Q2 earnings per share view $-0.13 -- Thomson Reuters I/B/E/S .On track to initiate phase 2/3 trial for PYL(TM) imaging agent and phase 1 trial for 1095 this year.  Full Article

Valeant and Progenics announce FDA approvals for relistor
Wednesday, 20 Jul 2016 

Progenics Pharmaceuticals Inc : Valeant expects to commence sales of relistor tablets in U.S. in Q3 of 2016 . Valeant and Progenics announce FDA approves relistor tablets for the treatment of opioid-induced constipation in adults with chronic non-cancer pain .FDA has approved relistor (methylnaltrexone bromide) tablets for treatment of opioid-induced constipation.  Full Article

Progenics Pharmaceuticals signs commercial license agreement with Selexis SA
Tuesday, 21 Jun 2016 

Press Release : Under agreement, progenics will have use of Selexis CHO-M cell line and sure technology platform . Financial terms were not disclosed .Progenics Pharmaceuticals, Inc. Signs commercial license agreement with Selexis SA for use of proprietary cell line and suretechnology platform.  Full Article

BRIEF-Progenics Says FDA Will Extend Review Of NDA For Azedra By Three Months

* PROGENICS PHARMACEUTICALS ANNOUNCES THREE-MONTH EXTENSION OF PDUFA DATE FOR AZEDRA (IOBENGUANE I 131)